{"id":1637,"date":"2026-02-10T13:07:31","date_gmt":"2026-02-10T13:07:31","guid":{"rendered":"https:\/\/admarebio.com\/news-events\/news-insights\/"},"modified":"2026-06-26T17:17:15","modified_gmt":"2026-06-26T17:17:15","slug":"kainova-therapeutics-secures-32m-cad-to-accelerate-development-of-immuno-oncology-and-inflammation-therapies","status":"publish","type":"post","link":"https:\/\/admarebio.com\/news-events\/news-insights\/kainova-therapeutics-secures-32m-cad-to-accelerate-development-of-immuno-oncology-and-inflammation-therapies\/","title":{"rendered":"Kainova Therapeutics Secures $32M CAD to Accelerate Development of Immuno-Oncology and Inflammation Therapies"},"content":{"rendered":"\n<p><strong>Montreal, Canada \u2013 Strasbourg, France \u2013 Boston, United States:&nbsp;<\/strong>Kainova Therapeutics (\u201cthe Company\u201d), a key player for breakthrough treatments for patients in immuno-oncology and inflammation, today announced the successful first close of its Series B financing round totaling $32 million CAD. This financing round was led by Investissement Qu\u00e9bec and was supported by existing investors CTI Life Sciences, Panacea Venture, 3B Future Health Fund, Seventure Partners, Viva BioInnovator, Turenne Capital, Schroders Capital, adMare BioInnovations, and Seido Capital.<\/p>\n\n\n\n<p>The investment demonstrates strong confidence in Kainova Therapeutics\u2019 strategic direction and supports the clinical advancement of its GPCR-targeting therapies. Lead asset DT-7012, a Treg-depleting anti-CCR8 antibody, is progressing in the ongoing Phase I\/II DOMISOL trial for the treatment of solid tumors. The Company is also advancing other GPCR-targeting therapies, including DT-9081, an EP4 antagonist for solid tumors and DT-9046, a small molecule biased antagonist of PAR2 for inflammatory conditions, further positioning Kainova Therapeutics as a leader in global precision medicine.<\/p>\n\n\n\n<p>Sean A. MacDonald, Chief Executive Officer of Kainova Therapeutics, said:&nbsp;<em>\u201cI am delighted to welcome Investissement Qu\u00e9bec as a new investor in the Company and deeply appreciate the continued commitment from our investors. This financing is a strong endorsement of our distinctive scientific strategy, our leadership in GPCR innovation, and our well-defined pipeline of high-value programs with significant commercial potential. Securing this investment is especially significant given the current challenging fundraising environment, but exceptional science is still rewarded, and Kainova Therapeutics remains focused on advancing its robust clinical pipeline of GPCR targeting therapies and delivering breakthrough treatments for patients worldwide.\u201d<\/em><\/p>\n\n\n\n<p>Laurence Rulleau, Chair of the Board, and Managing Partner, CTI Life Sciences Fund, commented:&nbsp;<em>\u201cThis financing marks a crucial moment in the realization of Kainova Therapeutics\u2019 clinical roadmap and corporate growth. The team achieved significant clinical milestones during 2025, positioning the company at the forefront of GPCR innovation and demonstrating potential of value creation. We look forward with enthusiasm and are pleased to welcome Investissement Qu\u00e9bec and Louis-Etienne Fortier to the Board of Directors to achieve the Company\u2019s potential and vision of transforming patients\u2019 lives.\u201d<\/em><\/p>\n\n\n\n<p>Bicha Ngo, President and Chief Executive Officer of Investissement Qu\u00e9bec, added:&nbsp;<em>\u201cInvestissement Qu\u00e9bec is pleased to support the research and development of innovative solutions in a critical industry like life sciences. Through our participation in this significant financing effort, we are contributing to the relocation of the Company\u2019s headquarters to Qu\u00e9bec and laying the groundwork for a team with unique expertise in pharmaceutical development. Working in cooperation with the team at Kainova Therapeutics, we will deliver essential support to drive growth and foster further innovation.\u201d<\/em><\/p>\n\n\n\n<p><strong>ENDS<\/strong><\/p>\n\n\n\n<p><strong>For more information, please contact:<\/strong><br>Optimum Strategic Communications<br>Mary Clark, Zoe Bolt, Elena Bates, Nellie Stephens<br>+44 (0) 203 882 9621<br><a href=\"mailto:kainova@optimumcomms.com\">kainova@optimumcomms.com<\/a><\/p>\n\n\n\n<p>For French media:<br><a href=\"mailto:communication@kainovatx.com\">communication@kainovatx.com<\/a><\/p>\n\n\n\n<p><strong>About Kainova Therapeutics<\/strong><\/p>\n\n\n\n<p>Kainova Therapeutics is a clinical-stage biopharmaceutical company, headquartered in Montreal, Canada, driving a robust pipeline of breakthrough therapies that precisely modulate G protein-coupled receptors (GPCRs) to transform patient outcomes, particularly in immuno-oncology and inflammation. Kainova Therapeutics\u2019 key programs include a unique clinical stage Treg-depleting anti-CCR8 antibody with differentiated competitive features and a first in-class pre-IND stage biased antagonist of PAR2.<\/p>\n\n\n\n<p>By unlocking challenging and unexploited GPCR targets through its validated approach that integrates deep biological knowledge, Kainova Therapeutics delivers highly differentiated therapies designed to address unmet medical needs and improve therapeutic efficacy. Grounded in scientific excellence and recognized for a solid track record of collaborations with major pharma, physicians and KOLs worldwide, Kainova Therapeutics creates long-term value in competitive and fast-expanding markets.<\/p>\n\n\n\n<p>Operating in North America, France, and Australia, Kainova Therapeutics is progressing with clinical momentum towards global commercialization. As GPCRs gain renewed attention as next-generation drug targets, Kainova Therapeutics is uniquely positioned to lead the field, combining deep biological insight with commercial maturity to drive global impact. For more information, please visit https:\/\/www.kainovatx.com<\/p>\n\n\n\n<p><strong>About Investissement Qu\u00e9bec<\/strong><\/p>\n\n\n\n<p>Investissement Qu\u00e9bec&#8217;s mission is to actively participate in the economic development of Quebec by stimulating innovation in businesses, entrepreneurship and takeover as well as the growth of investment and exports. Active in all administrative regions of Quebec, the Company supports the creation and development of businesses of all sizes through investments and adapted financial solutions. Investissement Qu\u00e9bec also supports businesses through advisory services and other support measures, notably through the Impulsion PME program, an initiative of the Government of Quebec (MEIE). For more information, please visit https:\/\/www.investquebec.com<\/p>\n\n\n\n<p><a href=\"https:\/\/www.kainovatx.com\/en\/press-releases\/kainova-therapeutics-secures-32m-cad-to-accelerate-development-of-immuno-oncology-and-inflammation-therapies\/\">Read the original press release<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Montreal, Canada \u2013 Strasbourg, France \u2013 Boston, United States:&nbsp;Kainova Therapeutics (\u201cthe Company\u201d), a key player for breakthrough treatments for patients in immuno-oncology and inflammation, today announced the successful first close [&hellip;]<\/p>\n","protected":false},"author":4,"featured_media":1632,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[29],"tags":[],"company":[79],"class_list":["post-1637","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-portfolio-companies"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Kainova Therapeutics Secures $32M CAD to Accelerate Development of Immuno-Oncology and Inflammation Therapies | adMare<\/title>\n<meta name=\"robots\" content=\"noindex, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Kainova Therapeutics Secures $32M CAD to Accelerate Development of Immuno-Oncology and Inflammation Therapies | adMare\" \/>\n<meta property=\"og:description\" content=\"Montreal, Canada \u2013 Strasbourg, France \u2013 Boston, United States:&nbsp;Kainova Therapeutics (\u201cthe Company\u201d), a key player for breakthrough treatments for patients in immuno-oncology and inflammation, today announced the successful first close [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/admarebio.com\/news-events\/news-insights\/kainova-therapeutics-secures-32m-cad-to-accelerate-development-of-immuno-oncology-and-inflammation-therapies\/\" \/>\n<meta property=\"og:site_name\" content=\"adMare\" \/>\n<meta property=\"article:published_time\" content=\"2026-02-10T13:07:31+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-06-26T17:17:15+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/admarebio.com\/wp-content\/uploads\/2026\/05\/zymeworks-en-1768231861-1.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1198\" \/>\n\t<meta property=\"og:image:height\" content=\"628\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Earnscliffe Strategies\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Earnscliffe Strategies\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/admarebio.com\\\/news-events\\\/news-insights\\\/kainova-therapeutics-secures-32m-cad-to-accelerate-development-of-immuno-oncology-and-inflammation-therapies\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/admarebio.com\\\/news-events\\\/news-insights\\\/kainova-therapeutics-secures-32m-cad-to-accelerate-development-of-immuno-oncology-and-inflammation-therapies\\\/\"},\"author\":{\"name\":\"Earnscliffe Strategies\",\"@id\":\"https:\\\/\\\/admarebio.com\\\/en\\\/#\\\/schema\\\/person\\\/bd78e975574bdbf66541602c00a312da\"},\"headline\":\"Kainova Therapeutics Secures $32M CAD to Accelerate Development of Immuno-Oncology and Inflammation Therapies\",\"datePublished\":\"2026-02-10T13:07:31+00:00\",\"dateModified\":\"2026-06-26T17:17:15+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/admarebio.com\\\/news-events\\\/news-insights\\\/kainova-therapeutics-secures-32m-cad-to-accelerate-development-of-immuno-oncology-and-inflammation-therapies\\\/\"},\"wordCount\":756,\"publisher\":{\"@id\":\"https:\\\/\\\/admarebio.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/admarebio.com\\\/news-events\\\/news-insights\\\/kainova-therapeutics-secures-32m-cad-to-accelerate-development-of-immuno-oncology-and-inflammation-therapies\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/admarebio.com\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/zymeworks-en-1768231861-1.png\",\"articleSection\":[\"Portfolio Companies\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/admarebio.com\\\/news-events\\\/news-insights\\\/kainova-therapeutics-secures-32m-cad-to-accelerate-development-of-immuno-oncology-and-inflammation-therapies\\\/\",\"url\":\"https:\\\/\\\/admarebio.com\\\/news-events\\\/news-insights\\\/kainova-therapeutics-secures-32m-cad-to-accelerate-development-of-immuno-oncology-and-inflammation-therapies\\\/\",\"name\":\"Kainova Therapeutics Secures $32M CAD to Accelerate Development of Immuno-Oncology and Inflammation Therapies | adMare\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/admarebio.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/admarebio.com\\\/news-events\\\/news-insights\\\/kainova-therapeutics-secures-32m-cad-to-accelerate-development-of-immuno-oncology-and-inflammation-therapies\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/admarebio.com\\\/news-events\\\/news-insights\\\/kainova-therapeutics-secures-32m-cad-to-accelerate-development-of-immuno-oncology-and-inflammation-therapies\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/admarebio.com\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/zymeworks-en-1768231861-1.png\",\"datePublished\":\"2026-02-10T13:07:31+00:00\",\"dateModified\":\"2026-06-26T17:17:15+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/admarebio.com\\\/news-events\\\/news-insights\\\/kainova-therapeutics-secures-32m-cad-to-accelerate-development-of-immuno-oncology-and-inflammation-therapies\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/admarebio.com\\\/news-events\\\/news-insights\\\/kainova-therapeutics-secures-32m-cad-to-accelerate-development-of-immuno-oncology-and-inflammation-therapies\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/admarebio.com\\\/news-events\\\/news-insights\\\/kainova-therapeutics-secures-32m-cad-to-accelerate-development-of-immuno-oncology-and-inflammation-therapies\\\/#primaryimage\",\"url\":\"https:\\\/\\\/admarebio.com\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/zymeworks-en-1768231861-1.png\",\"contentUrl\":\"https:\\\/\\\/admarebio.com\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/zymeworks-en-1768231861-1.png\",\"width\":1198,\"height\":628},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/admarebio.com\\\/news-events\\\/news-insights\\\/kainova-therapeutics-secures-32m-cad-to-accelerate-development-of-immuno-oncology-and-inflammation-therapies\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/admarebio.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"News &#038; Events\",\"item\":\"https:\\\/\\\/admarebio.com\\\/en\\\/news-events\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"News &#038; Insights\",\"item\":\"https:\\\/\\\/admarebio.com\\\/en\\\/news-events\\\/news-insights\\\/\"},{\"@type\":\"ListItem\",\"position\":4,\"name\":\"Kainova Therapeutics Secures $32M CAD to Accelerate Development of Immuno-Oncology and Inflammation Therapies\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/admarebio.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/admarebio.com\\\/en\\\/\",\"name\":\"adMare\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/admarebio.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/admarebio.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/admarebio.com\\\/en\\\/#organization\",\"name\":\"adMare\",\"url\":\"https:\\\/\\\/admarebio.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/admarebio.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/admarebio.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/Logo-light.svg\",\"contentUrl\":\"https:\\\/\\\/admarebio.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/Logo-light.svg\",\"width\":915,\"height\":337,\"caption\":\"adMare\"},\"image\":{\"@id\":\"https:\\\/\\\/admarebio.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/admarebio.com\\\/en\\\/#\\\/schema\\\/person\\\/bd78e975574bdbf66541602c00a312da\",\"name\":\"Earnscliffe Strategies\",\"url\":\"#\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Kainova Therapeutics Secures $32M CAD to Accelerate Development of Immuno-Oncology and Inflammation Therapies | adMare","robots":{"index":"noindex","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"og_locale":"en_US","og_type":"article","og_title":"Kainova Therapeutics Secures $32M CAD to Accelerate Development of Immuno-Oncology and Inflammation Therapies | adMare","og_description":"Montreal, Canada \u2013 Strasbourg, France \u2013 Boston, United States:&nbsp;Kainova Therapeutics (\u201cthe Company\u201d), a key player for breakthrough treatments for patients in immuno-oncology and inflammation, today announced the successful first close [&hellip;]","og_url":"https:\/\/admarebio.com\/news-events\/news-insights\/kainova-therapeutics-secures-32m-cad-to-accelerate-development-of-immuno-oncology-and-inflammation-therapies\/","og_site_name":"adMare","article_published_time":"2026-02-10T13:07:31+00:00","article_modified_time":"2026-06-26T17:17:15+00:00","og_image":[{"width":1198,"height":628,"url":"https:\/\/admarebio.com\/wp-content\/uploads\/2026\/05\/zymeworks-en-1768231861-1.png","type":"image\/png"}],"author":"Earnscliffe Strategies","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Earnscliffe Strategies","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/admarebio.com\/news-events\/news-insights\/kainova-therapeutics-secures-32m-cad-to-accelerate-development-of-immuno-oncology-and-inflammation-therapies\/#article","isPartOf":{"@id":"https:\/\/admarebio.com\/news-events\/news-insights\/kainova-therapeutics-secures-32m-cad-to-accelerate-development-of-immuno-oncology-and-inflammation-therapies\/"},"author":{"name":"Earnscliffe Strategies","@id":"https:\/\/admarebio.com\/en\/#\/schema\/person\/bd78e975574bdbf66541602c00a312da"},"headline":"Kainova Therapeutics Secures $32M CAD to Accelerate Development of Immuno-Oncology and Inflammation Therapies","datePublished":"2026-02-10T13:07:31+00:00","dateModified":"2026-06-26T17:17:15+00:00","mainEntityOfPage":{"@id":"https:\/\/admarebio.com\/news-events\/news-insights\/kainova-therapeutics-secures-32m-cad-to-accelerate-development-of-immuno-oncology-and-inflammation-therapies\/"},"wordCount":756,"publisher":{"@id":"https:\/\/admarebio.com\/en\/#organization"},"image":{"@id":"https:\/\/admarebio.com\/news-events\/news-insights\/kainova-therapeutics-secures-32m-cad-to-accelerate-development-of-immuno-oncology-and-inflammation-therapies\/#primaryimage"},"thumbnailUrl":"https:\/\/admarebio.com\/wp-content\/uploads\/2026\/05\/zymeworks-en-1768231861-1.png","articleSection":["Portfolio Companies"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/admarebio.com\/news-events\/news-insights\/kainova-therapeutics-secures-32m-cad-to-accelerate-development-of-immuno-oncology-and-inflammation-therapies\/","url":"https:\/\/admarebio.com\/news-events\/news-insights\/kainova-therapeutics-secures-32m-cad-to-accelerate-development-of-immuno-oncology-and-inflammation-therapies\/","name":"Kainova Therapeutics Secures $32M CAD to Accelerate Development of Immuno-Oncology and Inflammation Therapies | adMare","isPartOf":{"@id":"https:\/\/admarebio.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/admarebio.com\/news-events\/news-insights\/kainova-therapeutics-secures-32m-cad-to-accelerate-development-of-immuno-oncology-and-inflammation-therapies\/#primaryimage"},"image":{"@id":"https:\/\/admarebio.com\/news-events\/news-insights\/kainova-therapeutics-secures-32m-cad-to-accelerate-development-of-immuno-oncology-and-inflammation-therapies\/#primaryimage"},"thumbnailUrl":"https:\/\/admarebio.com\/wp-content\/uploads\/2026\/05\/zymeworks-en-1768231861-1.png","datePublished":"2026-02-10T13:07:31+00:00","dateModified":"2026-06-26T17:17:15+00:00","breadcrumb":{"@id":"https:\/\/admarebio.com\/news-events\/news-insights\/kainova-therapeutics-secures-32m-cad-to-accelerate-development-of-immuno-oncology-and-inflammation-therapies\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/admarebio.com\/news-events\/news-insights\/kainova-therapeutics-secures-32m-cad-to-accelerate-development-of-immuno-oncology-and-inflammation-therapies\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/admarebio.com\/news-events\/news-insights\/kainova-therapeutics-secures-32m-cad-to-accelerate-development-of-immuno-oncology-and-inflammation-therapies\/#primaryimage","url":"https:\/\/admarebio.com\/wp-content\/uploads\/2026\/05\/zymeworks-en-1768231861-1.png","contentUrl":"https:\/\/admarebio.com\/wp-content\/uploads\/2026\/05\/zymeworks-en-1768231861-1.png","width":1198,"height":628},{"@type":"BreadcrumbList","@id":"https:\/\/admarebio.com\/news-events\/news-insights\/kainova-therapeutics-secures-32m-cad-to-accelerate-development-of-immuno-oncology-and-inflammation-therapies\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/admarebio.com\/en\/"},{"@type":"ListItem","position":2,"name":"News &#038; Events","item":"https:\/\/admarebio.com\/en\/news-events\/"},{"@type":"ListItem","position":3,"name":"News &#038; Insights","item":"https:\/\/admarebio.com\/en\/news-events\/news-insights\/"},{"@type":"ListItem","position":4,"name":"Kainova Therapeutics Secures $32M CAD to Accelerate Development of Immuno-Oncology and Inflammation Therapies"}]},{"@type":"WebSite","@id":"https:\/\/admarebio.com\/en\/#website","url":"https:\/\/admarebio.com\/en\/","name":"adMare","description":"","publisher":{"@id":"https:\/\/admarebio.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/admarebio.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/admarebio.com\/en\/#organization","name":"adMare","url":"https:\/\/admarebio.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/admarebio.com\/en\/#\/schema\/logo\/image\/","url":"https:\/\/admarebio.com\/wp-content\/uploads\/2026\/03\/Logo-light.svg","contentUrl":"https:\/\/admarebio.com\/wp-content\/uploads\/2026\/03\/Logo-light.svg","width":915,"height":337,"caption":"adMare"},"image":{"@id":"https:\/\/admarebio.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/admarebio.com\/en\/#\/schema\/person\/bd78e975574bdbf66541602c00a312da","name":"Earnscliffe Strategies","url":"#"}]}},"_links":{"self":[{"href":"https:\/\/admarebio.com\/en\/wp-json\/wp\/v2\/posts\/1637","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/admarebio.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/admarebio.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/admarebio.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/admarebio.com\/en\/wp-json\/wp\/v2\/comments?post=1637"}],"version-history":[{"count":1,"href":"https:\/\/admarebio.com\/en\/wp-json\/wp\/v2\/posts\/1637\/revisions"}],"predecessor-version":[{"id":1638,"href":"https:\/\/admarebio.com\/en\/wp-json\/wp\/v2\/posts\/1637\/revisions\/1638"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/admarebio.com\/en\/wp-json\/wp\/v2\/media\/1632"}],"wp:attachment":[{"href":"https:\/\/admarebio.com\/en\/wp-json\/wp\/v2\/media?parent=1637"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/admarebio.com\/en\/wp-json\/wp\/v2\/categories?post=1637"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/admarebio.com\/en\/wp-json\/wp\/v2\/tags?post=1637"},{"taxonomy":"company","embeddable":true,"href":"https:\/\/admarebio.com\/en\/wp-json\/wp\/v2\/company?post=1637"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}